We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+2.98%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$714M
AUM Growth
-$7.08M
Cap. Flow
-$12.4M
Cap. Flow %
-1.73%
Top 10 Hldgs %
12.22%
Holding
2,427
New
525
Increased
471
Reduced
569
Closed
774

Sector Composition

Rank Sector Weight
1 Technology 10.87%
2 Real Estate 9.87%
3 Consumer Discretionary 9.69%
4 Industrials 8.7%
5 Healthcare 8.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NWY
1051
DELISTED
New York & Co Inc
NWY
$64K 0.01%
23,800
KDP icon
1052
Keurig Dr Pepper
KDP
$40.8B
$63K 0.01%
859
-5
-0.6% -$382
MLR icon
1053
Miller Industries
MLR
$619M
$63K 0.01%
3,153
-799
-20% -$17.6K
NOC icon
1054
Northrop Grumman
NOC
$81.2B
$63K 0.01%
400
-196
-33% -$31.4K
SUPN icon
1055
Supernus Pharmaceuticals
SUPN
$2.77B
$63K 0.01%
3,700
-2,100
-36% -$29.9K
TFX icon
1056
Teleflex
TFX
$5.98B
$63K 0.01%
465
-99
-18% -$12.6K
ENZ
1057
DELISTED
Enzo Biochem, Inc.
ENZ
$63K 0.01%
20,900
-4,300
-17% -$12.1K
SYNH
1058
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$63K 0.01%
1,569
-28
-2% -$966
CTXS
1059
CALL
DELISTED
Citrix Systems Inc
CTXS
$63K 0.01%
+1,130
New +$60K
BLMN icon
1060
Bloomin' Brands
BLMN
$937M
$62K 0.01%
2,900
-5,000
-63% -$113K
NBIX icon
1061
Neurocrine Biosciences
NBIX
$16.6B
$62K 0.01%
1,300
+800
+160% +$33.9K
OMCL icon
1062
Omnicell
OMCL
$1.68B
$62K 0.01%
+1,650
New +$60.2K
RGEN icon
1063
Repligen
RGEN
$9.25B
$62K 0.01%
+1,500
New +$55K
PGTI
1064
DELISTED
PGT, Inc.
PGTI
$62K 0.01%
+4,300
New +$53.3K
ISEE
1065
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$62K 0.01%
+1,200
New +$59.7K
CMD
1066
DELISTED
Cantel Medical Corporation
CMD
$62K 0.01%
+1,163
New +$56.6K
FPRX
1067
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$62K 0.01%
2,500
+300
+14% +$6.68K
AKAO
1068
DELISTED
Achaogen Inc
AKAO
$62K 0.01%
+10,300
New +$63.9K
SCLN
1069
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$62K 0.01%
6,300
+5,000
+385% +$45.5K
DNY
1070
DELISTED
DONNELLEY R R & SONS CO
DNY
$62K 0.01%
+3,533
New +$62K
NEE icon
1071
NextEra Energy
NEE
$177B
$61K 0.01%
2,504
-75,600
-97% -$1.92M
TNET icon
1072
TriNet
TNET
$3.14B
$61K 0.01%
+2,400
New +$75.1K
PRGX
1073
DELISTED
PRGX Global, Inc.
PRGX
$61K 0.01%
+14,000
New +$60.1K
RAI
1074
DELISTED
Reynolds American Inc
RAI
$61K 0.01%
1,640
-1,286
-44% -$48.2K
SGNT
1075
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$61K 0.01%
+2,500
New +$59.9K

Similar funds

Prelude Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Prelude Capital Management held 2,427 positions worth $714M, down 0.98% from $722M the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Prelude Capital Management's Q2 2015 filing shows 525 new, 471 increased, 569 reduced and 774 closed positions. Its largest new stake was EXCEL TRUST , INC COM STK: 322,846 shares worth $5.09M. The largest sale was TRW AUTOMOTIVE HOLDINGS CORP, an estimated $9.14M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, down from 12% a quarter earlier, followed by Real Estate and Consumer Discretionary.

  • Prelude Capital Management's largest Q2 2015 buy was EXCEL TRUST , INC COM STK: 322,846 shares worth $5.09M.
  • Prelude Capital Management added most to ANN INC in Q2 2015, an estimated $7.45M increase.
  • Prelude Capital Management's biggest Q2 2015 reduction was DaVita, cutting an estimated $3.22M.
  • Prelude Capital Management fully exited TRW AUTOMOTIVE HOLDINGS CORP in Q2 2015, selling an estimated $9.14M.
  • Prelude Capital Management's ten largest holdings make up 12% of its $714M portfolio in Q2 2015.
  • Prelude Capital Management opened 525 new positions and closed 774 in Q2 2015.
  • Prelude Capital Management's portfolio value fell 0.98% quarter-over-quarter to $714M.

Based on Prelude Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.